Congratulations to our client Ayala Pharmaceuticals.
REHOVOT, Israel and WILMINGTON, Del., May 07, 2020 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically define patient populations, today announced the pricing of its initial public offering of 3,666,667 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions raising gross proceeds of approximately $55 million.
Mark Cohen, Senior Partner and Chair of the Life Sciences Practice Group of the Firm represents Ayala Pharmaceuticals in its patent matters and intellectual property commercial matters.
